

Special Issue

Cholinergic System Neurodegeneration: Novel Pharmacotherapy

Message from the Guest Editors

This Special Issue, entitled “Cholinergic System Neurodegeneration: Novel therapies”, will mainly focus on the molecular, structural, neurochemical, pathological, and behavioral studies of the cholinergic system’s neurodegeneration, its impact on disease, and novel therapies used to avoid them. Acetylcholine was the first neurotransmitter identified by the studies of Henry Dale and Otto Loewi in 1936, which discovered chemical neurotransmission and afterwards the complex regulation of the cholinergic system and its functions. Cholinergic transmission regulates many functions peripherally (cardiovascular, gastrointestinal, respiratory, and reproductive systems, among others) and on the central nervous system (affective, memory, learning, and sleep regulation, among others), and its disruption is involved in different harmful neuropathologies. As I would be very pleased if you contributed to this Special Issue with either an original research paper or a focused review with emphasis on cholinergic system neurodegeneration and potential therapeutic approaches.

Guest Editors

Prof. Dr. Javier del Pino

Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, 28040 Madrid, Spain

Prof. Dr. Paula Moyano

Departamento de Farmacología y Toxicología, Universidad Complutense de Madrid, 28040 Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/209548

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).